Randomized Controlled Trial Multicenter Study Comparative Study
- Bionic Pancreas Research Group, Steven J Russell, Roy W Beck, Edward R Damiano, Firas H El-Khatib, Katrina J Ruedy, Courtney A Balliro, Zoey Li, Peter Calhoun, R Paul Wadwa, Bruce Buckingham, Keren Zhou, Mark Daniels, Philip Raskin, Perrin C White, Jane Lynch, Jeremy Pettus, Irl B Hirsch, Robin Goland, John B Buse, Davida Kruger, Nelly Mauras, Andrew Muir, Janet B McGill, Fran Cogen, Jill Weissberg-Benchell, Jordan S Sherwood, Luz E Castellanos, Mallory A Hillard, Marwa Tuffaha, Melissa S Putman, Mollie Y Sands, Gregory Forlenza, Robert Slover, Laurel H Messer, Erin Cobry, Viral N Shah, Sarit Polsky, Rayhan Lal, Laya Ekhlaspour, Michael S Hughes, Marina Basina, Betul Hatipoglu, Leann Olansky, Amrit Bhangoo, Nikta Forghani, Himala Kashmiri, Francoise Sutton, Abha Choudhary, Jimmy Penn, Rabab Jafri, Maria Rayas, Elia Escaname, Catherine Kerr, Ruby Favela-Prezas, Schafer Boeder, Subbulaxmi Trikudanathan, Kristen M Williams, Natasha Leibel, M Sue Kirkman, Kate Bergamo, Klara R Klein, Jean M Dostou, Sriram Machineni, Laura A Young, Jamie C Diner, Arti Bhan, J Kimberly Jones, Matthew Benson, Keisha Bird, Kimberly Englert, Joe Permuy, Kristina Cossen, Eric Felner, Maamoun Salam, Julie M Silverstein, Samantha Adamson, Andrea Cedeno, Seema Meighan, and Andrew Dauber.
- The authors' affiliations are as follows: the Diabetes Research Center, Massachusetts General Hospital (S.J.R., C.A.B., J.S.S., L.E.C., M.A.H., M.T., M.S.P., M.Y.S.), and Boston University (E.R.D.), Boston, and Beta Bionics, Concord (E.R.D., F.H.E.-K.) - all in Massachusetts; the Jaeb Center for Health Research, Tampa (R.W.B., K.J.R., Z.L., P.C.), and Nemours Children's Health Jacksonville, Jacksonville (N.M., M. Benson, K. Bird, K.E., J. Permuy) - both in Florida; the Barbara Davis Center for Diabetes, University of Colorado, Aurora (R.P.W., G.F., R.S., L.H.M., E.C., V.N.S., S.P.); Stanford University School of Medicine, Palo Alto (B.B., R.L., L.E., M.S.H., M. Basina), Children's Hospital of Orange County, Orange (M.D., A. Bhangoo, N.F., H.K., F.S.), and the University of California, San Diego, La Jolla (J. Pettus, S.B.) - all in California; Cleveland Clinic, Cleveland (K.Z., B.H., L.O.); University of Texas Southwestern Medical Center, Dallas (P.R., P.C.W., A. Choudhary, J. Penn), and University of Texas Health Science Center, San Antonio (J.L., R.J., M.R., E.E., C.K., R.F.-P.); the University of Washington, Seattle (I.B.H., S.T.); the Naomi Berrie Diabetes Center, Columbia University, New York (R.G., K.M.W., N.L.); the University of North Carolina, Chapel Hill (J.B.B., M.S.K., K. Bergamo, K.R.K., J.M.D., S. Machineni, L.A.Y., J.C.D.); the Henry Ford Health System, Detroit (D.K., A. Bhan, J.K.J.); Emory University, Atlanta (A.M., K.C., E.F.); Washington University in St. Louis, St. Louis (J.B.M., M.S., J.M.S., S.A., A. Cedeno); Children's National Hospital, Washington, DC (F.C., S. Meighan, A.D.); and the Pritzker Department of Psychiatry and Behavioral Health, Ann and Robert Lurie Children's Hospital, Chicago (J.W.-B.).
- N. Engl. J. Med. 2022 Sep 29; 387 (13): 116111721161-1172.
BackgroundCurrently available semiautomated insulin-delivery systems require individualized insulin regimens for the initialization of therapy and meal doses based on carbohydrate counting for routine operation. In contrast, the bionic pancreas is initialized only on the basis of body weight, makes all dose decisions and delivers insulin autonomously, and uses meal announcements without carbohydrate counting.MethodsIn this 13-week, multicenter, randomized trial, we randomly assigned in a 2:1 ratio persons at least 6 years of age with type 1 diabetes either to receive bionic pancreas treatment with insulin aspart or insulin lispro or to receive standard care (defined as any insulin-delivery method with unblinded, real-time continuous glucose monitoring). The primary outcome was the glycated hemoglobin level at 13 weeks. The key secondary outcome was the percentage of time that the glucose level as assessed by continuous glucose monitoring was below 54 mg per deciliter; the prespecified noninferiority limit for this outcome was 1 percentage point. Safety was also assessed.ResultsA total of 219 participants 6 to 79 years of age were assigned to the bionic-pancreas group, and 107 to the standard-care group. The glycated hemoglobin level decreased from 7.9% to 7.3% in the bionic-pancreas group and did not change (was at 7.7% at both time points) in the standard-care group (mean adjusted difference at 13 weeks, -0.5 percentage points; 95% confidence interval [CI], -0.6 to -0.3; P<0.001). The percentage of time that the glucose level as assessed by continuous glucose monitoring was below 54 mg per deciliter did not differ significantly between the two groups (13-week adjusted difference, 0.0 percentage points; 95% CI, -0.1 to 0.04; P<0.001 for noninferiority). The rate of severe hypoglycemia was 17.7 events per 100 participant-years in the bionic-pancreas group and 10.8 events per 100 participant-years in the standard-care group (P = 0.39). No episodes of diabetic ketoacidosis occurred in either group.ConclusionsIn this 13-week, randomized trial involving adults and children with type 1 diabetes, use of a bionic pancreas was associated with a greater reduction than standard care in the glycated hemoglobin level. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; ClinicalTrials.gov number, NCT04200313.).Copyright © 2022 Massachusetts Medical Society.
Knowledge, pearl, summary or comment to share?
You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
- Superscript can be denoted by
- Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens
- Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)inline.
- Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document
[^1]: This is a long footnote..